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Evaluating the kinetics of cell-free DNA (cfDNA) in the blood of
cancer patients could be a strong auxiliary component to the
molecular characterization of cfDNA, but its potential clinical sig-
niﬁcance is obscured by the absence of an analytical consensus. To
utilize quantitative cfDNA assessment with conﬁdence, it is crucial
that the preanalytical phase is standardized. In a previous publica-
tion, several preanalytical variables that may affect quantitative
measurements of cfDNA were identiﬁed, and the most confounding
variables were assessed further using the growth medium of cul-
tured cancer cells as a source of cfDNA (“Cell-free DNA: Preanalytical
variables” [1]). The data accompanying this report relates to these
experiments, which includes numerous changes to the sample
handling and isolation protocols, and can be used for the inter-
pretation of these results and other similar experiments by different
researchers.
& 2015 Published by Elsevier Inc. This is an open access article under
the CC BY license (http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableubject area Biochemistry, molecular biology
ore speciﬁc sub-
ject areaClinical biochemistry, translational oncology, prenatal diagnosticsis an open access article under the CC BY license
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ow data was
acquiredPCR ampliﬁcation of cell-free DNA was measured using a real-time quanti-
tative assay for the β-globin gene. All assays were performed on a Rotor-
Gene Q detection system (Qiagen) using a 72 well ring-setup.ata format Analyzed
xperimental
factorsCentrifugation, medium storage temperature, medium thawing temperature,
medium storage tube type, treatment with denaturing agents, combining
snap freezing with proteinase K, binding buffer type, elution volume, elution
regime and elution tube type.xperimental
featuresCell-free DNA was extracted directly from growth medium collected from
143B osteosarcoma cells in culture, and then quantiﬁed by real-time PCR.
Several variations to the standard procedure were evaluated.ata source
locationSouth Africaata accessibility The data is with this articleDValue of the data This data will be useful considerations when optimizing protocols and setting up a standard
operating procedure, which should expedite the translation of cfDNA analyses to clinical practice.
 This data could be compared to other studies that investigated the effect of methodological vari-
ables on quantitative measurements of cfDNA.
 This data could be used to interpret studies that investigated the effect of methodological variables
on qualitative measurements of cfDNA.1. Data
In order to investigate the effects of several adjustments to the preanalytical phase of quantitative
cfDNA measurements, the growth medium of cultured cancer cells was used as a source of cfDNA. The
data in this report was obtained by amplifying cfDNA with real-time PCR, after it had been extracted
under different preanalytical conditions. The data is presented in a supplementary ﬁle as a single
table, which includes several quantitative measurements of cfDNA following modiﬁcations to the
standard protocol followed. These changes are described in Table 1.2. Experimental design, materials and methods
2.1. Cell culturing
Culture medium of the human bone cancer (osteosarcoma) cell line 143B (ATCCs CRL-8303™) was
used as a source of cfDNA. Given that DNA levels in growth medium ﬂuctuate much like cfDNA in the
blood of humans, we could use it as a model to evaluate the effect of different variables on both high
and low concentrations of cfDNA. Cells were cultured in T75 ﬂasks in Dulbecco's Modiﬁed Eagle's
medium (DMEM) (HyClone; SH30243.01) supplemented with 10% fetal bovine serum (Biochrom;
S0615) and 1% penicillin/streptomycin (Lonza; DE17-602E) at 37 °C in humidiﬁed air and 5% CO2. After
the cells have reached the necessary conﬂuency, the culture medium was removed, processed and
stored at 80 °C in 15 ml tubes.
Table 1
Modiﬁcations to standard procedure.
Modiﬁcations to sample handling
Modiﬁcation to standard
procedure
Description
Centrifugation regime Growth medium was centrifuged for 10 min at different forces (1000, 5000, 10 000
and 20,000 g). Other samples were subject to two rounds of centrifugation, ﬁrst at
1000 g and then transferred to new tubes before the next centrifugation at 5000,
10,000 and 20,000 g, respectively. After centrifugation all samples were transferred
to new tubes.
Growth medium storage
temperature
After centrifugation, growth medium was transferred to fresh tubes and stored until
cfDNA was extracted. Three storage schemes were tested: 20 °C, 80 °C, and snap-
freezing in liquid nitrogen followed by storage at 80 °C.
Growth medium thawing
temperature
Prior to cfDNA extraction, the growth medium is thawed. Two approaches were
tested: thawing of growth medium at room temperature, and at 37 °C in a tem-
perature controlled water bath for 5 min.
Growth medium storage tube type After collection and processing, growth medium was stored in three different tubes:
15 mL nuclease free tubes (Ambion), regular 1.5 mL tubes (Eppendorf), and DNA
LoBind tubes (Eppendorf).
Modiﬁcations to cfDNA extraction
protocol
Treatment with denaturing agents Prior to cfDNA extraction, growth mediumwas treated with SDS (0.05%), proteinase K
(1.5 mg/mL), and a combination of the two for 30 min at 50 °C, respectively. In the
cases where SDS was used, buffer NTB was used instead of buffer NTI. As the kit
makes no suggestions regarding the use of proteinase K, buffer NTI was used in this
case.
Effect of combining snap freezing
with proteinase K
Four different scenarios were compared: (1) cfDNA was extracted from growth
medium directly after collection, (2) Growth medium was treated with proteinase K
immediately after collection, followed by cfDNA extraction, (3) Growth medium was
snap frozen before cfDNA extraction, and (4) Growth medium was snap frozen and
then thawed and treated with proteinase K prior to extraction.
Binding buffer type After thawing, growth medium is mixed with binding buffer before it is added to the
spin column. Here, we compared two binding buffers, NTI and NTB. In the case of
buffer NTB, the ratio of sample to buffer is 1:5. In the case of extractions where buffer
NTI is used, the sample to buffer ratio is only 1:2.
Elution volume CfDNA was extracted and eluted into 20 μL, 40 μL, 60 μL, and 100 μL of elution buffer,
respectively.
Elution regime CfDNA was extracted and eluted into 20 μL of elution buffer and repeated twice more
to have a ﬁnal volume of 60 μL. This was followed by the elution of DNA into 30 μL
elution buffer and repeated once more to achieve a ﬁnal volume of 60 μL. The former
was compared to DNA eluted into 60 μL of elution buffer once.
Elution tube type To examine the loss of eluted DNA due to adsorption to tube walls, regular 1.5 mL
tubes (Eppendorf) were compared with 1.5 mL DNA LoBind tubes (Eppendorf)
Comparing different protocols
Non-optimized Media was collected and centrifuged at 1000 g and transferred to fresh 1.5 mL
Eppendorf DNA LoBind tubes and stored at 20 °C. Before extraction, the medium
was thawed at room temperature, and no denaturing agent was added thereafter.
CfDNAwas then extracted and eluted into 20 μL of elution buffer in one step. Samples
were stored in 1.5 mL DNA LoBind tubes (Eppendorf)
Optimized Media was collected and centrifuged at 10,000 g and transferred to fresh 15 mL
tubes (Ambion). The media was then snap-frozen in liquid nitrogen and stored at
80 °C. The samples were then thawed at 37 °C, and incubated with proteinase K
(1.5 mg/mL) for 30 min at 37 °C. CfDNA was extracted and eluted into 60 mL of elution
buffer in three steps (320 mL) into regular 1.5 mL tubes (Eppendorf)
QIAmp DSP virus kit CfDNA was extracted according to the instructions provided by the manufacturer.
Increasing the yield of cfDNA
Effect of media evaporation For each replicate, 6 mL of growth medium was aliquot into 2 mL tubes and evapo-
rated in a SpeedVac to a total volume of 2.5 mL
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CfDNA was extracted with the NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel, Düren,
Germany; 1502/001), according to the instructions described by the PCR clean-up user manual.
Brieﬂy, samples were removed from the 80 °C freezer and thawed at 37 °C and then vortexed and
centrifuged brieﬂy. For each biological replicate, cfDNA was extracted in triplicate. For every sample,
600 mL of growth mediumwas mixed with 1200 mL of binding buffer. Samples were then vortexed, the
entire volume of growth media was added to the spin column in small regiments, and centrifuged at
11 000 g for 1 min at room temperature. The columns were then washed twice, followed by the
elution of cfDNA into 20 mL of elution buffer.
2.3. Quantiﬁcation of cell-free DNA
PCR ampliﬁcation of cfDNA was measured using a real-time quantitative assay for the β-globin
gene. All assays were performed on a Rotor-Gene Q detection system (Qiagen) using a 72 well ring-
setup. The reaction mixture consisted of 2 μL DNA and 23 μL master mix, which was composed of
8.1 μL H2O, 12.5 μL TaqMan Universal MasterMix (Life technologies; 1502032), 0.4 μL of 10 μM dual
ﬂuorescent probe 50-(FAM)AAG GTG AAC GTG GAT GAA GTT GGT GG(TAMRA)-30, and 1 μL of 10 μM
forward and reverse primers, respectively. The primers used were: F1, 50-GTG CAC CTG ACT CCT GAG
GAG A-30, and R1, 50-CCT TGA TAC CAA CCT GCC CAG-30. These probe and primers were synthesized by
Integrated DNA Technologies (IDT, Whitehead Scientiﬁc). PCR conditions were set to: 95 °C for 10 min,
followed by 45 cycles of 15 s denaturation at 95 °C, 1 min annealing at 60 °C, followed by 30 s
extension at 72 °C. Sequence data of β-globin is attainable from GenBank (accession number:
U01317). The absolute concentration of the target gene was calculated by using a standard curve. In
this study, a standard curve was generated using ﬁve-fold serial dilutions of genomic DNA (50,000,
5000, 500, 50 and 5 pg/mL). Each biological replicate was quantiﬁed in duplicate, and triplicates of the
standard curve were included in each run (only assays with R2 values40.99 for the standard curve
were used).Acknowledgments
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